Intracochlear administration of DB-OTO Gene Therapy in pediatric patients with profound hearing loss due to otoferlin mutations: the CHORD Phase 1 / 2 open-label trial

Zoom

Intracochlear administration of DB-OTO Gene Therapy in pediatric patients with profound hearing loss due to otoferlin mutations: the CHORD Phase 1 / 2 open-label trial

Eduardo Corrales, MD

1. Learn from state of the art gene therapy for pediatric patients with deafness

2. Identify the auditory neuropathy spectrum disease of pediatric patients with otoferlin deficiency

3. Be able to acknowledge gene therapy treatment for patients with otoferlin mutation and profound sensorineural hearing loss